Search Results

Genentech is letting go of 118 employees in San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.

Shingrix sales in the US took a 15% dive in the third quarter. GSK is now the second Big Pharma to report declining vaccine sales, after Sanofi reported a similar decline last week.

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a genetic thyroid disorder.

The Company looks to build on its recent momentum - receiving FDA approval to expand its pivotal clinical trial into the second and final stage

X-ray crystallography is a powerful tool for fragment-based drug discovery (FBDD), providing detailed insights into fragment binding and enabling structure-guided optimization. In this talk, Dr. May Sharpe will present the Fast Fragment and Compound Screening (FFCS) pipeline at the Swiss Light Source (PSI) and share the first results from a collaborative screening campaign with Chemspace, featuring the REAL Crystallographic Fragment Library — the first dataset acquired at the newly upgraded SLS2.0 PXIII beamline.

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing troubles for the franchise.